Sanderling Venture Partners VI LP - 23 Jan 2024 Form 4 Insider Report for CalciMedica, Inc. (CALC)

Role
10%+ Owner
Signature
/s/ Sanderling Venture Partners VI, L.P., By: /s/ Timothy C. Mills, Managing Director of Middleton, McNeil & Mills Associates VI, L.P., its General Partner
Issuer symbol
CALC
Transactions as of
23 Jan 2024
Net transactions value
+$2,600,003
Form type
4
Filing time
25 Jan 2024, 20:00:32 UTC
Previous filing
10 Oct 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CALC Common Stock Purchase $900,904 +243,356 +35% $3.70 946,744 23 Jan 2024 Direct F1
transaction CALC Common Stock Purchase $535,591 +144,676 +25% $3.70 727,433 23 Jan 2024 By Sanderling Venture Partners VI Co-Investment Fund, L.P. F1
transaction CALC Common Stock Purchase $719,935 +194,472 +81% $3.70 435,148 23 Jan 2024 By Sanderling Ventures VII, L.P. F1
transaction CALC Common Stock Purchase $188,920 +51,032 +81% $3.70 114,260 23 Jan 2024 By Sanderling Ventures VII (Canada), L.P. F1
transaction CALC Common Stock Purchase $48,807 +13,184 +91% $3.70 27,609 23 Jan 2024 By Sanderling Ventures VII Annex Fund, L.P. F1
transaction CALC Common Stock Purchase $14,512 +3,920 +22% $3.70 21,602 23 Jan 2024 By Sanderling Ventures Management VI F1
transaction CALC Common Stock Purchase $106,410 +28,744 +1857% $3.70 30,292 23 Jan 2024 By Sanderling Ventures Management VII F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CALC Warrant Purchase $15,210 +121,678 $0.1250* 121,678 23 Jan 2024 Common Stock 121,678 $5.36 Direct F1, F2
transaction CALC Warrant Purchase $15,210 +121,678 $0.1250* 121,678 23 Jan 2024 Common Stock 121,678 $7.15 Direct F1, F3
transaction CALC Warrant Purchase $9,042 +72,338 $0.1250* 72,338 23 Jan 2024 Common Stock 72,338 $5.36 By Sanderling Venture Partners VI Co-Investment Fund, L.P. F1, F2
transaction CALC Warrant Purchase $9,042 +72,338 $0.1250* 72,338 23 Jan 2024 Common Stock 72,338 $7.15 By Sanderling Venture Partners VI Co-Investment Fund, L.P. F1, F3
transaction CALC Warrant Purchase $12,154 +97,236 $0.1250* 97,236 23 Jan 2024 Common Stock 97,236 $5.36 By Sanderling Ventures VII, L.P. F1, F2
transaction CALC Warrant Purchase $12,154 +97,236 $0.1250* 97,236 23 Jan 2024 Common Stock 97,236 $7.15 By Sanderling Ventures VII, L.P. F1, F3
transaction CALC Warrant Purchase $3,190 +25,516 $0.1250* 25,516 23 Jan 2024 Common Stock 25,516 $5.36 By Sanderling Ventures VII (Canada), L.P. F1, F2
transaction CALC Warrant Purchase $3,190 +25,516 $0.1250* 25,516 23 Jan 2024 Common Stock 25,516 $7.15 By Sanderling Ventures VII (Canada), L.P. F1, F3
transaction CALC Warrant Purchase $824 +6,592 $0.1250* 6,592 23 Jan 2024 Common Stock 6,592 $5.36 By Sanderling Ventures VII Annex Fund, L.P. F1, F2
transaction CALC Warrant Purchase $824 +6,592 $0.1250* 6,592 23 Jan 2024 Common Stock 6,592 $7.15 By Sanderling Ventures VII Annex Fund, L.P. F1, F3
transaction CALC Warrant Purchase $245 +1,960 $0.1250* 1,960 23 Jan 2024 Common Stock 1,960 $5.36 By Sanderling Ventures Management VI F1, F2
transaction CALC Warrant Purchase $245 +1,960 $0.1250* 1,960 23 Jan 2024 Common Stock 1,960 $7.15 By Sanderling Ventures Management VI F1, F3
transaction CALC Warrant Purchase $1,796 +14,372 $0.1250* 14,372 23 Jan 2024 Common Stock 14,372 $5.36 By Sanderling Ventures Management VII F1, F2
transaction CALC Warrant Purchase $1,796 +14,372 $0.1250* 14,372 23 Jan 2024 Common Stock 14,372 $7.15 By Sanderling Ventures Management VII F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.
F2 The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.
F3 The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.